Skip to main content
SpringerLink
Log in

Lp(a) Metabolism

  • Chapter
  • First Online:
Lipoprotein(a)

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Lp(a) is an LDL-like lipoprotein of unknown function that is found in a wide range of concentrations in plasma among individuals. In the years since its discovery over 60 years ago much has been learned about the metabolism of Lp(a). It has been found that the production rate of the apo(a) component of Lp(a) is the major factor that determines the Lp(a) concentration in plasma, something that is largely under genetic control. The factors that control the clearance of Lp(a) are poorly understood and there is evidence supporting the concept that Lp(a) clearance is mediated through multiple receptor pathways rather than predominantly through a single pathway as occurs for LDL. This chapter highlights the factors that are thought to control Lp(a) production and clearance as well as the effects of lipid altering drugs on Lp(a) metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ajufo E, Rader DJ. Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol. 2016;4:436–46.

    CAS  PubMed  Google Scholar 

  • Artemeva NV, Safarova MS, Ezhov MV, Afanasieva OI, Dmitrieva OA, Pokrovsky SN. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype. Atheroscler Suppl. 2015;18:53–8.

    CAS  PubMed  Google Scholar 

  • Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Horkko S, Krauss RM, Chapman MJ, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230–9.

    CAS  PubMed  Google Scholar 

  • Bersot TP, Innerarity TL, Pitas RE, Rall SC Jr, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest. 1986;77:622–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bonen DK, Hausman AM, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem. 1997;272:5659–67.

    CAS  PubMed  Google Scholar 

  • Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46:2681–91.

    CAS  PubMed  Google Scholar 

  • Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28.

    CAS  PubMed  Google Scholar 

  • Croyal M, Ouguerram K, Passard M, Ferchaud-Roucher V, Chetiveaux M, Billon-Crossouard S, de Gouville AC, Lambert G, Krempf M, Nobecourt E. Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2015;35:2042–7.

    CAS  PubMed  Google Scholar 

  • Demant T, Seeberg K, Bedynek A, Seidel D. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis. 2001;157:325–39.

    CAS  PubMed  Google Scholar 

  • Diffenderfer MR, Lamon-Fava S, Marcovina SM, Barrett PH, Lel J, Dolnikowski GG, Berglund L, Schaefer EJ. Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metabolism. 2016;65:381–90.

    CAS  PubMed  Google Scholar 

  • Gemin M, Romagnuolo R, McIntyre AD, Scipione CA, Seidah NG, Boffa MB, Hegele RA, Koschinsky ML. Sortilin promotes secretion of apolipoprotein(a) by hepatic cells. Circulation. 2018;134:A20583.

    Google Scholar 

  • Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990;85:1542–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–60.

    CAS  PubMed  Google Scholar 

  • Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987;84:6919–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jadeja RN, Jones MA, Fromal O, Powell FL, Khurana S, Singh N, Martin PM. Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis. Aging (Albany NY). 2019;11:386–400.

    CAS  PubMed  Google Scholar 

  • Jenner JL, Seman LJ, Millar JS, Lamon-Fava S, Welty FK, Dolnikowski GG, Marcovina SM, Lichtenstein AH, Barrett PH, deLuca C, et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism. 2005;54:361–9.

    CAS  PubMed  Google Scholar 

  • Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240–9.

    CAS  PubMed  Google Scholar 

  • Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991;87:227–37.

    CAS  PubMed  Google Scholar 

  • Koschinsky ML, Tomlinson JE, Zioncheck TF, Schwartz K, Eaton DL, Lawn RM. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 1991;30:5044–51.

    CAS  PubMed  Google Scholar 

  • Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313–9.

    CAS  PubMed  Google Scholar 

  • Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:522–8.

    CAS  PubMed  Google Scholar 

  • Krempler F, Kostner G, Bolzano K, Sandhofer F. Studies on the metabolism of the lipoprotein Lp (a) in man. Atherosclerosis. 1978;30:57–65.

    CAS  PubMed  Google Scholar 

  • Krempler F, Kostner G, Bolzano K, Sandhofer F. Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B. Biochim Biophys Acta. 1979;575:63–70.

    CAS  PubMed  Google Scholar 

  • Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest. 1980;65:1483–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273:6–30.

    CAS  PubMed  Google Scholar 

  • Lanktree MB, Anand SS, Yusuf S, Hegele RA, Investigators S. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 2010;3:39–46.

    CAS  PubMed  Google Scholar 

  • Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54:2815–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li J, Lange LA, Sabourin J, Duan Q, Valdar W, Willis MS, Li Y, Wilson JG, Lange EM. Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. J Hum Genet. 2015;60:755–61.

    PubMed  Google Scholar 

  • Mack S, Coassin S, Rueedi R, Yousri NA, Seppala I, Gieger C, Schonherr S, Forer L, Erhart G, Marques-Vidal P, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J Lipid Res. 2017;58:1834–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, Gugliucci A, Movsesyan I, Ishida BY, Chu C, et al. Effects of the absence of apolipoprotein E on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228–36.

    PubMed  PubMed Central  Google Scholar 

  • McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–7.

    CAS  PubMed  Google Scholar 

  • Mefford MT, Marcovina SM, Bittner V, Cushman M, Brown TM, Farkouh ME, Tsimikas S, Monda KL, Lopez JAG, Muntner P, et al. PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. J Lipid Res. 2019;60:1946–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, et al. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. J Lipid Res. 2018;59:2397–402.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nicholls SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, Deeg MA, Krueger KA, Nissen SE. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016;10:519–527.e4.

    PubMed  Google Scholar 

  • Niemeier A, Willnow T, Dieplinger H, Jacobsen C, Meyer N, Hilpert J, Beisiegel U. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol. 1999;19:552–61.

    CAS  PubMed  Google Scholar 

  • Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital lp(a) deficiency: a frequent apo(a) ‘null’ mutation in caucasians. Hum Mol Genet. 1999;8:2087–96.

    CAS  PubMed  Google Scholar 

  • Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:2686–93.

    CAS  PubMed  Google Scholar 

  • Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022–32.

    PubMed  Google Scholar 

  • Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91:443–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rainwater DL, Ludwig MJ, Haffner SM, VandeBerg JL. Lipid and lipoprotein factors associated with variation in Lp(a) density. Arterioscler Thromb Vasc Biol. 1995;15:313–9.

    CAS  PubMed  Google Scholar 

  • Reblin T, Niemeier A, Meyer N, Willnow TE, Kronenberg F, Dieplinger H, Greten H, Beisiegel U. Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J Lipid Res. 1997;38:2103–10.

    CAS  PubMed  Google Scholar 

  • Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Romagnuolo R, Scipione CA, Marcovina SM, Gemin M, Seidah NG, Boffa MB, Koschinsky ML. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. PLoS One. 2017;12:e0180869.

    PubMed  PubMed Central  Google Scholar 

  • Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 1991;115:209–18.

    CAS  PubMed  Google Scholar 

  • Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57:1339–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sharma M, Redpath GM, Williams MJ, McCormick SP. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ Res. 2017;120:1091–102.

    CAS  PubMed  Google Scholar 

  • Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutations. Circ J. 2016;80:512–8.

    CAS  PubMed  Google Scholar 

  • Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E, Bartlett VJ, Kingsbury J, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2017;37:1770–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Trinder M, DeCastro ML, Azizi H, Cermakova L, Jackson LM, Frohlich J, Mancini GBJ, Francis GA, Brunham LR. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:2682–93.

    CAS  PubMed  Google Scholar 

  • Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008;19:369–77.

    CAS  PubMed  Google Scholar 

  • Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020a;41:2275–84.

    CAS  PubMed  Google Scholar 

  • Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020b;382:244–55.

    CAS  PubMed  Google Scholar 

  • Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, Lader E, Rader DJ. Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy. Pharmacogenet Genomics. 2017;27:285–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80:458–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36:2239–45.

    CAS  PubMed  Google Scholar 

  • von Zychlinski A, Kleffmann T, Williams MJ, McCormick SP. Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteome. 2011;74:2881–91.

    Google Scholar 

  • Watts GF, Chan DC, Pang J, Ma L, Ying Q, Aggarwal S, Marcovina SM, Barrett PHR. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism. 2020;107:154221.

    CAS  PubMed  Google Scholar 

  • White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res. 1993;34:509–17.

    CAS  PubMed  Google Scholar 

  • White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for “null” lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem. 1994;269:9060–6.

    CAS  PubMed  Google Scholar 

  • Yang XP, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, Kurlander RJ, Patterson AP, Becker LC, Remaley AT. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res. 2013;54:2450–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, Miller YI, Witztum JL, Tsimikas S. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57:706–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol. 2016;31:440–50.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    John S. Millar & Daniel J. Rader

  2. Institute for Diabetes Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    John S. Millar & Daniel J. Rader

  3. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Daniel J. Rader

  4. Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Daniel J. Rader

  5. Smilow Center for Translational Research, University of Pennsylvania, Philadelphia, PA, USA

    Daniel J. Rader

Authors
  1. John S. Millar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Rader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Rader .

Editor information

Editors and Affiliations

  1. Mater Hospital, University of Queensland, Brisbane, QLD, Australia

    Karam Kostner

  2. Medical University of Graz, Graz, Austria

    Gerhard M. Kostner

  3. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Millar, J.S., Rader, D.J. (2023). Lp(a) Metabolism. In: Kostner, K., Kostner, G.M., Toth, P.P. (eds) Lipoprotein(a). Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-031-24575-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-24575-6_4

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-24574-9

  • Online ISBN: 978-3-031-24575-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation